Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

Biochemical and Biophysical Research Communications

Volumn 390, Issue 3, 2009, Pages 613-618

  Kim Chung, Le Thi ^a   Hosaka, Toshio ^a   Yoshida, Masaki ^a   Harada, Nagakatsu ^a   Sakaue, Hiroshi ^a   Sakai, Tohru ^a   Nakaya, Yutaka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Adiponectin; Exendin 4; GLP 1

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; INTERLEUKIN 6; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL SECRETION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-METHYL-3-ISOBUTYLXANTHINE; 3T3-L1 CELLS; ADIPOCYTES; ADIPOKINES; ADIPONECTIN; ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FORSKOLIN; GLUCAGON-LIKE PEPTIDE 1; INFLAMMATION; INSULIN RESISTANCE; ISOQUINOLINES; MICE; PEPTIDES; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE INHIBITORS; RECEPTORS, GLUCAGON; RNA, MESSENGER; SULFONAMIDES; VENOMS;

EID: 70449701437     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.015     Document Type: Article

References (40)

1. Hansen K.B., Knop F.K., Holst J.J., and Vilsboll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int. J. Clin. Pract. 63 (2009) 1154-1160
2. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267 (1992) 7402-7405
3. Greig N.H., Holloway H.W., De Ore K.A., Jani D., Wang Y., Zhou J., Garant M.J., and Egan J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42 (1999) 45-50
4. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., and Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 (1999) 1026-1034
5. Idris I., Patiag D., Gray S., and Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem. Pharmacol. 63 (2002) 993-996
6. Sancho V., Nuche B., Arnes L., Cancelas J., Gonzalez N., Diaz-Miguel M., Martin-Duce A., Valverde I., and Villanueva-Penacarrillo M.L. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. Int. J. Mol. Med. 19 (2007) 961-966
7. Gao H., Wang X., Zhang Z., Yang Y., Yang J., Li X., and Ning G. GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32 (2007) 90-95
8. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., and Tataranni P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86 (2001) 1930-1935
9. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
10. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
11. Antuna-Puente B., Feve B., Fellahi S., and Bastard J.P. Obesity, inflammation and insulin resistance: which role for adipokines. Therapie 62 (2007) 285-292
12. Park S., Dong X., Fisher T.L., Dunn S., Omer A.K., Weir G., and White M.F. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 281 (2006) 1159-1168
13. Montrose-Rafizadeh C., Yang H., Wang Y., Roth J., Montrose M.H., and Adams L.G. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J. Cell. Physiol. 172 (1997) 275-283
14. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
15. Fasshauer M., Klein J., Neumann S., Eszlinger M., and Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 507 (2001) 142-146
16. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., and Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273 (1998) 15559-15564
17. Huai Q., Wang H., Zhang W., Colman R.W., Robinson H., and Ke H. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. USA 101 (2004) 9624-9629
18. Alcantara A.I., Morales M., Delgado E., Lopez-Delgado M.I., Clemente F., Luque M.A., Malaisse W.J., Valverde I., and Villanueva-Penacarrillo M.L. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch. Biochem. Biophys. 341 (1997) 1-7
19. Gross D.N., Miyoshi H., Hosaka T., Zhang H.H., Pino E.C., Souza S., Obin M., Greenberg A.S., and Pilch P.F. Dynamics of lipid droplet-associated proteins during hormonally stimulated lipolysis in engineered adipocytes: stabilization and lipid droplet binding of adipocyte differentiation-related protein/adipophilin. Mol. Endocrinol. 20 (2006) 459-466
20. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., and Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116 (2006) 1494-1505
21. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
22. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E745-E751
23. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., and Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 301 (2003) 1045-1050
24. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271 (1996) 10697-10703
25. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1595-1599
26. Samson S.L., Gonzalez E.V., Yechoor V., Bajaj M., Oka K., and Chan L. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol. Ther. 16 (2008) 1805-1812
27. Brubaker P.L., and Drucker D.J. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 8 (2002) 179-188
28. Egan J.M., Montrose-Rafizadeh C., Wang Y., Bernier M., and Roth J. Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135 (1994) 2070-2075
29. Bullock B.P., Heller R.S., and Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137 (1996) 2968-2978
30. Cancelas J., Villanueva-Penacarrillo M.L., Valverde I., and Malaisse W.J. Suppression by exendin(9-39)amide of glucagon-like peptide-1 insulinotropic action in rats infused with dimethyl ester of succinic acid. Endocrine 15 (2001) 283-285
31. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab. 34 Suppl. 2 (2008) S73-S77
32. Holz G.G. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53 (2004) 5-13
33. Sancho V., Trigo M.V., Gonzalez N., Valverde I., Malaisse W.J., and Villanueva-Penacarrillo M.L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol. Endocrinol. 35 (2005) 27-38
34. Murao K., Li J., Imachi H., Muraoka T., Masugata H., Zhang G.X., Kobayashi R., Ishida T., and Tokumitsu H. Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line. Diabetes Obes. Metab. 11 (2009) 939-946
35. Dulin N.O., Niu J., Browning D.D., Ye R.D., and Voyno-Yasenetskaya T. Cyclic AMP-independent activation of protein kinase A by vasoactive peptides. J. Biol. Chem. 276 (2001) 20827-20830
36. + controls cell surface expression of Na,K-ATPase via a cAMP-independent PKA pathway in mammalian kidney collecting duct cells. Mol. Biol. Cell 14 (2003) 2677-2688
37. Gwosdow A.R., O'Connell N.A., and Abou-Samra A.B. Interleukin-1 increases protein kinase A activity by a cAMP-independent mechanism in AtT-20 cells. Am. J. Physiol. 266 (1994) E79-E84
38. Klover P.J., Zimmers T.A., Koniaris L.G., and Mooney R.A. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52 (2003) 2784-2789
39. Senn J.J., Klover P.J., Nowak I.A., and Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002) 3391-3399
40. Rotter V., Nagaev I., and Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278 (2003) 45777-45784